Key Takeaways
- • EQT-backed Cerba Healthcare has initiated supervised restructuring proceedings at the French commercial court (Tribunal des Activités Économiques de Nanterre) to address approximately €5bn in debt and strengthen its liquidity position.
- • The private laboratory operator extended its grace period on interest payments through November following a lender agreement last month, and received a €100m liquidity loan from EQT earlier this year.
- • Reimbursement tariff negotiations with France's National Health Authorities represent a critical variable in the restructuring, with initial outcomes expected by end-September; a French supervisory body previously recommended reducing reimbursement levels.
- • Despite financial pressure, Cerba reported improved operating performance in Q2, suggesting underlying operational strength independent of its capital structure challenges.
- • The conciliation framework allows Cerba and creditors extended time to negotiate a longer-term balance sheet restructuring solution, with discussions having intensified following mounting debt pressure earlier in 2026.
Summary
EQT-backed Cerba Healthcare, a French private laboratory and healthcare diagnostics operator, has filed for supervised restructuring proceedings with the Tribunal des Activités Économiques de Nanterre as it confronts a debt burden of approximately €5bn. The company initiated conciliation proceedings to establish a formal framework for negotiations with creditors regarding its capital structure, according to Bloomberg reporting.
The restructuring effort represents a response to mounting financial pressure that accumulated throughout 2026. Cerba began creditor discussions earlier this year after its debt load came under increasing strain. To buy additional time, the company secured an extension of its grace period covering interest payments on borrowings through November following an agreement reached last month. Additionally, EQT provided a €100m liquidity loan earlier in the year to shore up cash reserves.
A pivotal element of the restructuring will be Cerba's ability to improve cash generation through favorable reimbursement terms for its diagnostic services. The company is actively negotiating with France's National Health Authorities over government-supported reimbursement tariffs for medical testing, with management expecting initial outcomes by end-September. These discussions carry heightened importance given that a French supervisory body recommended last year that reimbursement levels be reduced—a headwind that directly impacts the company's revenue visibility. Management had previously expected greater clarity on the pricing environment during Q2, but negotiations have extended beyond initial timelines.
Notably, despite the capital structure challenges, Cerba demonstrated improved operating performance in Q2, suggesting the underlying business operations remain relatively resilient. This operational strength may provide a foundation for creditors to support a restructuring solution that preserves going-concern value. EQT, PSP Investments (a minority shareholder), and the company itself declined to provide detailed commentary on the proceedings, limiting disclosure beyond the court filing itself.
The restructuring effort represents a response to mounting financial pressure that accumulated throughout 2026. Cerba began creditor discussions earlier this year after its debt load came under increasing strain. To buy additional time, the company secured an extension of its grace period covering interest payments on borrowings through November following an agreement reached last month. Additionally, EQT provided a €100m liquidity loan earlier in the year to shore up cash reserves.
A pivotal element of the restructuring will be Cerba's ability to improve cash generation through favorable reimbursement terms for its diagnostic services. The company is actively negotiating with France's National Health Authorities over government-supported reimbursement tariffs for medical testing, with management expecting initial outcomes by end-September. These discussions carry heightened importance given that a French supervisory body recommended last year that reimbursement levels be reduced—a headwind that directly impacts the company's revenue visibility. Management had previously expected greater clarity on the pricing environment during Q2, but negotiations have extended beyond initial timelines.
Notably, despite the capital structure challenges, Cerba demonstrated improved operating performance in Q2, suggesting the underlying business operations remain relatively resilient. This operational strength may provide a foundation for creditors to support a restructuring solution that preserves going-concern value. EQT, PSP Investments (a minority shareholder), and the company itself declined to provide detailed commentary on the proceedings, limiting disclosure beyond the court filing itself.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.